TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03911609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Task
Description: The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
Study: NCT03297359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: daily subcutaneous injection of weight-adjusted dalteparin
Study: NCT02779582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone
Description: The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
Study: NCT04337905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHD-VR diagnosis tool
Description: Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADHD-VR diagnosis tool
Description: Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments.
Study: NCT03415971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG befor denture treatment
Study: NCT02779582

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill with no effect
Study: NCT03797976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIP and MEP
Description: Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
Study: NCT04800055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attractive Targeted Sugar Bait
Description: ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
Study: NCT03208959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1090
Description: IDO/TDO inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1090
Description: IDO/TDO inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1090
Description: IDO/TDO inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1090
Description: IDO/TDO inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1090
Description: IDO/TDO inhibitor
Study: NCT03500939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical oxygen
Description: inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: e.g. thrombectomy, thrombolysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: e.g. thrombectomy, thrombolysis
Study: NCT03974594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Tablets
Description: Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
Study: NCT04033939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02925065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-traditional group guitar instruction
Description: A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-traditional group guitar instruction
Description: A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
Study: NCT02047942

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Center-based cardiac rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based training with telemonitoring guidance
Study: NCT03845179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP receptor antagonist
Description: Used for infusion on study days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GIP receptor antagonist
Description: Used for infusion on study days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitor
Description: Oral administration of DPP-4 inhibitor in active treatment period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Oral administration of placebo tablet in placebo treatment period
Study: NCT04050332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair Walking
Description: Walking up and down stairs for four minutes at a comfortable pace
Study: NCT03454633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the temperature of hypothermic circulatory arrest
Description: Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the temperature of hypothermic circulatory arrest
Description: Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
Study: NCT01945099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro-PH20
Study: NCT02323906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Investigational new drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Kinase inhibitor
Study: NCT02883673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jada System
Description: It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
Study: NCT01901991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radioactive seed localization (RSL)
Description: Localization of nonpalpable breast lesions with Radioactive seed localization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wire-guided localization (WGL)
Description: Localization of nonpalpable breast lesions with Wire-guided localization
Study: NCT03415971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG befor denture treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EMG befor denture treatment
Study: NCT00500409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteoform
Description: Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHELCAL
Description: Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
Study: NCT04340414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow ECMO driving by CVVH machine
Description: With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
Study: NCT02424565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IODEX® balm
Description: 2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo balm
Description: 2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
Study: NCT03790085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablet
Study: NCT01518452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed JM working memory training
Description: daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed JM working memory training after waiting
Description: Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
Study: NCT03575039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaFlow II Transcatheter Aortic Valve System
Description: VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
Study: NCT03090009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: 100 mg twice a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo group
Study: NCT03944486

Intervention type: DEVICE
Group type: OTHER
Intervention: Feasibility of OnTrack
Description: Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
Study: NCT00877175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% tropicamide and 2.5% phenylephrine
Description: For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% tropicamide and 2.5% phenylephrine
Description: For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
Study: NCT04841239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal topical formulation
Study: NCT01965652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine 0.2 mg tablet taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once a day
Study: NCT04027010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy U tablet application
Description: There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms.
Study: NCT04199117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Untailored outreach
Description: Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Untailored outreach
Description: Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
Study: NCT03723590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esterified Hyaluronic Acid Matrix
Description: A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
Study: NCT04164485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Functional collagen scaffold transplantation
Description: Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose cell transplantation
Description: Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
Study: NCT03952156

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102.
Study: NCT01129154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusions of Panitumumab
Description: Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
Study: NCT02416583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT04199117

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Untailored outreach
Description: Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
Study: NCT02416583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane sweeping
Study: NCT00884130

Intervention type: PROCEDURE
Intervention: laparoscopic colorectal resection

Intervention type: PROCEDURE
Intervention: open colorectal resection
Study: NCT02466100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goals of care
Description: . Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
Study: NCT03650400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant
Description: Chewable tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant
Description: Chewable tablet
Study: NCT01195571

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: cmv vaccine
Description: dose escalation study of 4 towne-toledo chimera vaccines
Study: NCT03721848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy community clinic NCD+MH
Description: NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy community clinic NCD
Description: i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures
Study: NCT03872271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ileal pouch-anal anastomosis with diverting loop ileastomy
Description: Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
Study: NCT04252482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 12 weeks
Study: NCT03425279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-AXL-ADC
Description: Conditionally active biologic anti-AXL antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-AXL-ADC
Description: Conditionally active biologic anti-AXL antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor